Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the specification:

Listing of Claims:

1-78. (Canceled)

79. (Previously Presented) A composition which comprises a suitable carrier and an effective amount of a monoclonal antibody, which monoclonal antibody is produced by a method comprising:
(a) fusing a lymphoid cell capable of producing antibody with a trioma cell which does not produce any antibody and is obtained by fusing a heteromyeloma cell which does not produce any antibody with a human lymphoid cell so as to thereby form tetroma cells;
(b) incubating the tetroma cells formed in step (a) under conditions permissive for the production of antibody by the tetroma cells, so as to thereby produce the monoclonal antibody; and
(c) recovering the monoclonal antibody so produced.

80. (Previously Presented) The composition of claim 79, wherein the monoclonal antibody is specific for an antigen associated with a condition in a subject.

81. (Previously Presented) The composition of claim 80, wherein the condition is cancer and the amount of monoclonal antibody is sufficient to inhibit the growth of or eliminate the cancer.

82. (Previously Presented) The composition of claim 81, wherein the cancer is breast cancer, thyroid cancer or prostate cancer.

83-88. (Canceled)

89. (Previously Presented) The composition of claim 80, wherein the monoclonal antibody is coupled to an effector molecule.

90. (Previously Presented) The composition of claim 89, wherein the effector molecule is a cytotoxic agent, drug, enzyme, dye, or radioisotope.

91. (Previously Presented) The composition of claim 80, wherein the monoclonal antibody is coupled to a carrier.

92. (Previously Presented) The composition of claim 91, wherein the carrier is a liposome.

93. (Previously Presented) A method of treating a condition in a subject comprising administering to the subject an amount of the composition of claim 80 effective to bind the antigen associated with the condition so as to treat the condition in the subject.

94. (Previously Presented) A method of preventing a condition in a subject comprising administering to the subject an amount of the composition of claim 80 effective to bind the antigen associated with the condition so as to prevent the condition in the subject.

95. (Previously Presented) The method of claim 94, wherein the subject previously exhibited the condition.

96. (Previously Presented) The method of claim 93 or 94 wherein the condition is associated with a cancer, a tumor, a toxin, an infectious agent, an enzyme dysfunction, a hormone dysfunction, an autoimmune disease, an immune dysfunction, a viral antigen, a bacterial antigen, a eukaryotic antigen, or rejection of a transplanted tissue.

97. (Canceled)

98. (Previously Presented) The method of claim 96, wherein the cancer is breast cancer.

99-100. (Canceled)

101. (Previously Presented) The method of claim 96, wherein the tumor is benign.

102-105. (Canceled)

106. (Previously Presented) The composition of claim 79, wherein the heteromyeloma cell is the cell designated B6B11 (ATCC accession number HB-12481).

107. (Previously Presented) The composition of claim 79, wherein the heteromyeloma cell is a B6B11-like cell.

108. (Previously Presented) The composition of claim 79, wherein the human lymphoid cell is a myeloma cell.

109. (Previously Presented) The composition of claim 79, wherein the human lymphoid cell is a splenocyte or a lymph node cell.

110. (Previously Presented) The composition of claim 79, wherein the trioma cell is the cell designated MFP-2 (ATCC accession number HB-12482).